Roche announces U.S. Food and Drug Administration acceptance of sBLA for Gazyva in SLE, with a decision expected by December 2026 based on phase III ALLEGORY data.
Written By: Pharmacally Medical News Desk
Roche has announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application (sBLA) for Gazyva (obinutuzumab) in systemic lupus erythematosus (SLE), marking an important regulatory step toward a potential new indication in a disease with significant unmet need.
The submission is based on results from the phase III ALLEGORY study (NCT04963296), the detailed findings of which have already been published in the New England Journal of Medicine and covered in our previous article.
The update confirms that the application has been accepted for review and sets a target decision timeline of December 2026, providing clarity on the next regulatory milestone.
The filing reflects a potential expansion beyond Gazyva’s existing approval in lupus nephritis, positioning the therapy for broader use across the SLE population, while parallel submission to European regulators underscores a coordinated global strategy.
According to Levi Garraway MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development, the therapy may offer improved disease control, higher likelihood of remission, and reduced dependence on long-term steroid use.
Albert T. Roy, President and CEO, Lupus Research Alliance highlighted the ongoing burden of SLE and the need for additional treatment options that can reduce flares and improve patient outcomes.
Overall, while the ALLEGORY data have already established clinical efficacy, the key development here is regulatory momentum, with the FDA’s acceptance signaling that Gazyva is advancing toward a potential approval in SLE and reinforcing its broader potential across immune-mediated diseases within an expanding immunology pipeline.
Reference